228 related articles for article (PubMed ID: 18452090)
21. An orally available small molecule BCL6 inhibitor effectively suppresses diffuse large B cell lymphoma cells growth in vitro and in vivo.
Xing Y; Guo W; Wu M; Xie J; Huang D; Hu P; Zhou M; Zhang L; Zhang Q; Wang P; Wang X; Wang G; Wu H; Zhou C; Chen Y; Liu M; Yi Z; Sun Z
Cancer Lett; 2022 Mar; 529():100-111. PubMed ID: 34990752
[TBL] [Abstract][Full Text] [Related]
22. The role of BCL6 in lymphomas and routes to therapy.
Wagner SD; Ahearne M; Ko Ferrigno P
Br J Haematol; 2011 Jan; 152(1):3-12. PubMed ID: 21083654
[TBL] [Abstract][Full Text] [Related]
23. BCL6 represses NFkappaB activity in diffuse large B-cell lymphomas.
Perez-Rosado A; Artiga M; Vargiu P; Sanchez-Aguilera A; Alvarez-Barrientos A; Piris M
J Pathol; 2008 Mar; 214(4):498-507. PubMed ID: 18189332
[TBL] [Abstract][Full Text] [Related]
24. Targeted epigenetic repression of a lymphoma oncogene by sequence-specific histone modifiers induces apoptosis in DLBCL.
Luo H; Schmidt JA; Lee YS; Oltz EM; Payton JE
Leuk Lymphoma; 2017 Feb; 58(2):445-456. PubMed ID: 27268204
[TBL] [Abstract][Full Text] [Related]
25. Prognostic significance of MYC, BCL2, and BCL6 rearrangements in patients with diffuse large B-cell lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab.
Akyurek N; Uner A; Benekli M; Barista I
Cancer; 2012 Sep; 118(17):4173-83. PubMed ID: 22213394
[TBL] [Abstract][Full Text] [Related]
26. A hybrid mechanism of action for BCL6 in B cells defined by formation of functionally distinct complexes at enhancers and promoters.
Hatzi K; Jiang Y; Huang C; Garrett-Bakelman F; Gearhart MD; Giannopoulou EG; Zumbo P; Kirouac K; Bhaskara S; Polo JM; Kormaksson M; MacKerell AD; Xue F; Mason CE; Hiebert SW; Prive GG; Cerchietti L; Bardwell VJ; Elemento O; Melnick A
Cell Rep; 2013 Aug; 4(3):578-88. PubMed ID: 23911289
[TBL] [Abstract][Full Text] [Related]
27. Discovery of an Irreversible and Cell-Active BCL6 Inhibitor Selectively Targeting Cys53 Located at the Protein-Protein Interaction Interface.
Sameshima T; Yamamoto T; Sano O; Sogabe S; Igaki S; Sakamoto K; Ida K; Gotou M; Imaeda Y; Sakamoto J; Miyahisa I
Biochemistry; 2018 Feb; 57(8):1369-1379. PubMed ID: 29293322
[TBL] [Abstract][Full Text] [Related]
28. The ansamycin antibiotic, rifamycin SV, inhibits BCL6 transcriptional repression and forms a complex with the BCL6-BTB/POZ domain.
Evans SE; Goult BT; Fairall L; Jamieson AG; Ko Ferrigno P; Ford R; Schwabe JW; Wagner SD
PLoS One; 2014; 9(3):e90889. PubMed ID: 24595451
[TBL] [Abstract][Full Text] [Related]
29. Constitutively activated STAT3 promotes cell proliferation and survival in the activated B-cell subtype of diffuse large B-cell lymphomas.
Ding BB; Yu JJ; Yu RY; Mendez LM; Shaknovich R; Zhang Y; Cattoretti G; Ye BH
Blood; 2008 Feb; 111(3):1515-23. PubMed ID: 17951530
[TBL] [Abstract][Full Text] [Related]
30. Clinical significance of 'double-hit' and 'double-expression' lymphomas.
Ma Z; Niu J; Cao Y; Pang X; Cui W; Zhang W; Li X
J Clin Pathol; 2020 Mar; 73(3):126-138. PubMed ID: 31615842
[TBL] [Abstract][Full Text] [Related]
31. Clinical Significance of
Ting CY; Chang KM; Kuan JW; Sathar J; Chew LP; Wong OJ; Yusuf Y; Wong L; Samsudin AT; Pana MNBM; Lee SK; Gopal NSR; Puri R; Ong TC; Bahari SK; Goh AS; Teoh CS
Int J Med Sci; 2019; 16(4):556-566. PubMed ID: 31171907
[No Abstract] [Full Text] [Related]
32. Clinical relevance of BCL2, BCL6, and MYC rearrangements in diffuse large B-cell lymphoma.
Kramer MH; Hermans J; Wijburg E; Philippo K; Geelen E; van Krieken JH; de Jong D; Maartense E; Schuuring E; Kluin PM
Blood; 1998 Nov; 92(9):3152-62. PubMed ID: 9787151
[TBL] [Abstract][Full Text] [Related]
33. Patients with double/triple copy number gains on C-MYC, BCL2, and/or BCL6 treated with standard chemotherapy have a similarly poor prognosis than those with high-grade B cell lymphoma with C-MYC and BCL2 and/or BCL6 rearrangements: a single-center experience on a consecutive cohort of large B cell lymphomas.
Willenbacher E; Willenbacher W; Weger R; Dominik W; Manzl C; Brunner A
Ann Hematol; 2020 Sep; 99(9):2125-2132. PubMed ID: 32613279
[TBL] [Abstract][Full Text] [Related]
34. Identification BCL6 and miR-30 family associating with Ibrutinib resistance in activated B-cell-like diffuse large B-cell lymphoma.
Li J; Huang Y; Zhang Y; Wen J; Chen Y; Wang L; Jiang P; Hu J
Med Oncol; 2021 Feb; 38(4):33. PubMed ID: 33629212
[TBL] [Abstract][Full Text] [Related]
35. MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma.
Horn H; Ziepert M; Becher C; Barth TF; Bernd HW; Feller AC; Klapper W; Hummel M; Stein H; Hansmann ML; Schmelter C; Möller P; Cogliatti S; Pfreundschuh M; Schmitz N; Trümper L; Siebert R; Loeffler M; Rosenwald A; Ott G;
Blood; 2013 Mar; 121(12):2253-63. PubMed ID: 23335369
[TBL] [Abstract][Full Text] [Related]
36. Deregulated BCL6 expression recapitulates the pathogenesis of human diffuse large B cell lymphomas in mice.
Cattoretti G; Pasqualucci L; Ballon G; Tam W; Nandula SV; Shen Q; Mo T; Murty VV; Dalla-Favera R
Cancer Cell; 2005 May; 7(5):445-55. PubMed ID: 15894265
[TBL] [Abstract][Full Text] [Related]
37. Distinctive patterns of BCL6 molecular alterations and their functional consequences in different subgroups of diffuse large B-cell lymphoma.
Iqbal J; Greiner TC; Patel K; Dave BJ; Smith L; Ji J; Wright G; Sanger WG; Pickering DL; Jain S; Horsman DE; Shen Y; Fu K; Weisenburger DD; Hans CP; Campo E; Gascoyne RD; Rosenwald A; Jaffe ES; Delabie J; Rimsza L; Ott G; Müller-Hermelink HK; Connors JM; Vose JM; McKeithan T; Staudt LM; Chan WC;
Leukemia; 2007 Nov; 21(11):2332-43. PubMed ID: 17625604
[TBL] [Abstract][Full Text] [Related]
38. PATZ1 expression correlates positively with BAX and negatively with BCL6 and survival in human diffuse large B cell lymphomas.
Franco R; Scognamiglio G; Valentino E; Vitiello M; Luciano A; Palma G; Arra C; La Mantia E; Panico L; Tenneriello V; Pinto A; Frigeri F; Capobianco G; Botti G; Cerchia L; De Chiara A; Fedele M
Oncotarget; 2016 Sep; 7(37):59158-59172. PubMed ID: 27494852
[TBL] [Abstract][Full Text] [Related]
39. BCL6 represses CHEK1 and suppresses DNA damage pathways in normal and malignant B-cells.
Ranuncolo SM; Polo JM; Melnick A
Blood Cells Mol Dis; 2008; 41(1):95-9. PubMed ID: 18346918
[TBL] [Abstract][Full Text] [Related]
40. Non-immunoglobulin/BCL6 gene fusion in diffuse large B-cell lymphoma: prognostic implications.
Ueda C; Akasaka T; Ohno H
Leuk Lymphoma; 2002 Jul; 43(7):1375-81. PubMed ID: 12389616
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
